Literature DB >> 26462290

Community mass treatment with azithromycin for trachoma: Factors associated with change in participation of children from the first to the second round.

Elizabeth N Ssemanda1, Harran Mkocha2, Joshua Levens1, Beatriz Munoz1, Sheila K West1.   

Abstract

BACKGROUND: Mass drug administration (MDA) with azithromycin is an important part of trachoma control programs. Maintaining high participation among children is challenging. AIM: We assessed factors identifying households with a child who changed participation from the first MDA to the second MDA compared to households where all children participated at both MDAs.
METHODS: Two case-control comparisons were conducted in 11 Tanzanian communities, which underwent MDA in 2008 and 2009. The first case group (n=165) was a random sample of households with a child who changed from a 2008 non-participant to a 2009 participant (delayed participant). The second case group (n=165) was a random sample of households with a child who went from a 2008 participant to a 2009 non-participant (change to non-participant). Controls (n=330) were a random sample of households where all children participated in both rounds. Risk factors were assessed using questionnaires asked of children's guardians. Logistic models with a random-intercept were used to estimate odds ratios and 95% confidence intervals.
RESULTS: Households with delayed participation were more likely to be in communities with fewer treatment days (OR=2.98, 95% CI=1.80-4.92) and assigned to Community Treatment Assistants (CTA) with a wide area to cover (OR=1.88, 95% CI=1.09-3.23). Households with change to non-participation were more likely to live further from the distribution site (OR=3.17, 95% CI=1.19-8.46), have the guardian born outside the village with short-term residency (OR=2.64, 95% CI=1.32-5.31), and be assigned to a male CTA (OR=1.75, 95% CI=1.08-2.83).
CONCLUSIONS: Factors related to program accessibility were associated with delayed participation and maintaining participation.

Entities:  

Keywords:  Trachoma; azithromycin; mass drug administration

Year:  2015        PMID: 26462290      PMCID: PMC4599782          DOI: 10.1016/j.cegh.2013.06.001

Source DB:  PubMed          Journal:  Clin Epidemiol Glob Health        ISSN: 2213-3984


  17 in total

1.  Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.

Authors:  Dianne Stare; Emma Harding-Esch; Beatriz Munoz; Robin Bailey; David Mabey; Martin Holland; Charlotte Gaydos; Sheila West
Journal:  Ophthalmic Epidemiol       Date:  2011-02       Impact factor: 1.648

2.  Refusal to take ivermectin: the associated 'risk' factors in Hoima district, Uganda.

Authors:  N B Semiyaga; O Lalobo; R Ndyomugyenyi
Journal:  Ann Trop Med Parasitol       Date:  2005-03

3.  Eliminating blinding trachoma.

Authors:  Joseph A Cook
Journal:  N Engl J Med       Date:  2008-04-24       Impact factor: 91.245

4.  Ivermectin-based control of onchocerciasis in northern Cameroon: individual factors influencing participation in community treatment.

Authors:  J Gardon; J M Macé; E Cadot; C Ogil; C Godin; M Boussinesq
Journal:  Trans R Soc Trop Med Hyg       Date:  1996 May-Jun       Impact factor: 2.184

5.  Epidemiology of ocular chlamydial infection in a trachoma-hyperendemic area.

Authors:  S K West; P Rapoza; B Muñoz; S Katala; H R Taylor
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

6.  An eye for inequality: how trachoma relates to poverty in Tanzania and Vietnam.

Authors:  Evertjan Jansen; Rob M P M Baltussen; Eddy van Doorslaer; Edith Ngirwamungu; Mai P Nguyen; Peter M Kilima
Journal:  Ophthalmic Epidemiol       Date:  2007 Sep-Oct       Impact factor: 1.648

7.  Is mass treatment the appropriate schistosomiasis elimination strategy?

Authors:  Veronica L Tallo; Hélène Carabin; Portia P Alday; Ernesto Balolong; Remigio M Olveda; Stephen T McGarvey
Journal:  Bull World Health Organ       Date:  2008-10       Impact factor: 9.408

8.  Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania.

Authors:  Sheila K West; Beatriz Munoz; Harran Mkocha; Charlotte A Gaydos; Thomas C Quinn
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

9.  Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds.

Authors:  Elizabeth N Ssemanda; Joshua Levens; Harran Mkocha; Beatriz Munoz; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2012-03-20

10.  Estimating household and community transmission of ocular Chlamydia trachomatis.

Authors:  Isobel M Blake; Matthew J Burton; Robin L Bailey; Anthony W Solomon; Sheila West; Beatriz Muñoz; Martin J Holland; David C W Mabey; Manoj Gambhir; María-Gloria Basáñez; Nicholas C Grassly
Journal:  PLoS Negl Trop Dis       Date:  2009-03-31
View more
  3 in total

Review 1.  Ocular Chlamydia trachomatis infection: elimination with mass drug administration.

Authors:  Meraf A Wolle; Sheila K West
Journal:  Expert Rev Anti Infect Ther       Date:  2019-02-18       Impact factor: 5.091

2.  Population coverage and factors associated with participation following a mass drug administration of azithromycin for trachoma elimination in Amhara, Ethiopia.

Authors:  Caleb D Ebert; Tigist Astale; Eshetu Sata; Mulat Zerihun; Andrew W Nute; Aisha E P Stewart; Demelash Gessese; Gedefaw Ayenew; Zebene Ayele; Berhanu Melak; Melsew Chanyalew; Bizuayehu Gashaw; Zerihun Tadesse; E Kelly Callahan; Samuel M Jenness; Scott D Nash
Journal:  Trop Med Int Health       Date:  2019-02-10       Impact factor: 2.622

3.  Non-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factors.

Authors:  Tansy Edwards; Elizabeth Allen; Emma M Harding-Esch; John Hart; Sarah E Burr; Martin J Holland; Ansumana Sillah; Sheila K West; David Mabey; Robin Bailey
Journal:  PLoS Negl Trop Dis       Date:  2014-08-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.